Total Payments
$100,998
2024 Payments
$5,130
Companies
49
Transactions
854
Medicare Patients
5,055
Medicare Billing
$448,705
Payment Breakdown by Category
Consulting$45,090 (44.6%)
Other$29,400 (29.1%)
Food & Beverage$15,724 (15.6%)
Travel$9,194 (9.1%)
Education$1,591 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $45,090 | 13 | 44.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,400 | 11 | 29.1% |
| Food and Beverage | $15,724 | 763 | 15.6% |
| Travel and Lodging | $9,194 | 37 | 9.1% |
| Education | $1,591 | 30 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $75,026 | 285 | $0 (2024) |
| Gilead Sciences, Inc. | $17,943 | 180 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,861 | 85 | $0 (2024) |
| Astellas Pharma US Inc | $1,099 | 20 | $0 (2024) |
| ABBVIE INC. | $900.93 | 52 | $0 (2024) |
| Janssen Biotech, Inc. | $729.85 | 56 | $0 (2023) |
| Janssen Products, LP | $525.93 | 6 | $0 (2020) |
| Theratechnologies Inc. | $357.95 | 21 | $0 (2022) |
| Paratek Pharmaceuticals, Inc. | $304.08 | 16 | $0 (2024) |
| GlaxoSmithKline, LLC. | $199.40 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,130 | 104 | ViiV Healthcare Company ($3,701) |
| 2023 | $2,406 | 115 | ViiV Healthcare Company ($897.43) |
| 2022 | $16,361 | 104 | ViiV Healthcare Company ($10,680) |
| 2021 | $35,562 | 132 | ViiV Healthcare Company ($34,176) |
| 2020 | $5,100 | 78 | ViiV Healthcare Company ($4,023) |
| 2019 | $10,864 | 107 | ViiV Healthcare Company ($9,319) |
| 2018 | $13,508 | 101 | ViiV Healthcare Company ($11,739) |
| 2017 | $12,068 | 113 | Gilead Sciences Inc ($10,468) |
All Payment Transactions
854 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Food and Beverage | Cash or cash equivalent | $18.60 | General |
| Category: Infectious Disease | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.84 | General |
| 12/12/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: HIV | ||||||
| 12/12/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: HIV | ||||||
| 12/10/2024 | Seqirus USA Inc | Flucelvax (Biological), Fluad | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: Vaccines | ||||||
| 12/09/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: HIV | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.82 | General |
| 11/19/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/18/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $27.65 | General |
| Category: HIV | ||||||
| 11/13/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $11.37 | General |
| Category: HIV | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.26 | General |
| 11/04/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Food and Beverage | In-kind items and services | $122.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/04/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $29.88 | General |
| Category: HIV | ||||||
| 10/31/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.61 | General |
| 10/30/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.99 | General |
| 10/28/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $26.67 | General |
| Category: HIV | ||||||
| 10/25/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: VACCINE | ||||||
| 10/18/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $27.85 | General |
| Category: HIV | ||||||
| 10/18/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Hepatitis B Vaccine | ||||||
| 10/16/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: HIV | ||||||
| 10/14/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: HIV | ||||||
| 09/27/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $9.06 | General |
| Category: VACCINE | ||||||
| 09/25/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $119.17 | General |
| Category: HIV | ||||||
| 09/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.14 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,062 | 1,718 | $226,238 | $92,953 |
| 2022 | 24 | 1,134 | 2,044 | $236,983 | $92,764 |
| 2021 | 25 | 1,273 | 2,218 | $271,523 | $118,390 |
| 2020 | 27 | 1,586 | 2,721 | $329,612 | $144,599 |
Total Patients
5,055
Total Services
8,701
Medicare Billing
$448,705
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 397 | 445 | $97,900 | $41,529 | 42.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 142 | 325 | $39,000 | $19,506 | 50.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 139 | $27,800 | $12,606 | 45.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 108 | $14,580 | $7,025 | 48.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 51 | 51 | $10,200 | $3,956 | 38.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 36 | 36 | $4,140 | $2,182 | 52.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $3,900 | $1,608 | 41.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 47 | 144 | $15,120 | $1,490 | 9.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 47 | 149 | $5,960 | $1,126 | 18.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 59 | 99 | $1,980 | $831.60 | 42.0% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 19 | 54 | $1,512 | $274.32 | 18.1% |
| 87086 | Bacterial colony count, urine | Office | 2023 | 27 | 34 | $1,190 | $268.94 | 22.6% |
| 87186 | Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral), microdilution or agar dilution | Office | 2023 | 16 | 23 | $920.00 | $195.02 | 21.2% |
| 85652 | Red blood cell sedimentation rate, to detect inflammation, automated | Office | 2023 | 20 | 56 | $1,120 | $148.40 | 13.3% |
| 87088 | Bacterial urine culture | Office | 2023 | 11 | 15 | $300.00 | $118.95 | 39.7% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 22 | 28 | $616.00 | $87.08 | 14.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 305 | 335 | $73,700 | $33,843 | 45.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 165 | 382 | $45,840 | $21,214 | 46.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 94 | 159 | $21,465 | $9,537 | 44.4% |
| 99219 | Initial hospital observation care per day, typically 50 minutes | Facility | 2022 | 75 | 75 | $18,225 | $7,247 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 47 | 60 | $12,000 | $5,769 | 48.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $5,525 | $2,592 | 46.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 56 | 193 | $20,265 | $1,979 | 9.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 62 | 209 | $8,360 | $1,590 | 19.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 17 | 17 | $3,400 | $1,488 | 43.8% |
About Dr. Anita Scribner, MD
Dr. Anita Scribner, MD is a Infectious Disease healthcare provider based in Longview, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225005705.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anita Scribner, MD has received a total of $100,998 in payments from pharmaceutical and medical device companies, with $5,130 received in 2024. These payments were reported across 854 transactions from 49 companies. The most common payment nature is "Consulting Fee" ($45,090).
As a Medicare-enrolled provider, Scribner has provided services to 5,055 Medicare beneficiaries, totaling 8,701 services with total Medicare billing of $448,705. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Internal Medicine
- Location Longview, TX
- Active Since 03/03/2006
- Last Updated 09/24/2019
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1225005705
Products in Payments
- CABENUVA (Biological) $31,696
- DOVATO (Drug) $8,984
- JULUCA (Drug) $4,421
- Epclusa (Drug) $3,907
- ISENTRESS (Drug) $608.71
- TRIUMEQ (Drug) $578.93
- SYMTUZA (Drug) $510.99
- PREZCOBIX (Drug) $448.84
- ZERBAXA (Drug) $364.53
- NUZYRA (Drug) $304.08
- PIFELTRO (Drug) $292.72
- DELSTRIGO (Drug) $283.93
- Symtuza (Drug) $274.03
- EGRIFTA (Drug) $273.21
- Biktarvy (Drug) $243.00
- RUKOBIA (Drug) $235.99
- SHINGRIX (Biological) $199.40
- UBRELVY (Drug) $179.32
- QULIPTA (Drug) $134.74
- INJECTAFER (Drug) $114.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.